Posted on November 13, 2015
In Part 1 of our “What You Need to Know About Processed Meat, Red Meat and Cancer Risk” series, Oncology Dietitian Rhone Levin broke down the International Agency for Research on Cancer and World Health Organization’s (WHO) recent report “Carcinogenicity of consumption of red and processed meat” (which found positive links between consuming red and processed meats and 18 types of cancer) and gave some of examples of processed meats, read meats and protein alternatives.
Now, we’re discussing reducing your cancer risk and ways to incorporate more plant foods.
Posted on November 10, 2015
You’ve probably heard the news on the International Agency for Research on Cancer and World Health Organization’s (WHO) recent report “Carcinogenicity of consumption of red and processed meat,” which found positive links between consuming red and processed meats and 18 types of cancer.
The organization concluded there is enough evidence to place processed meats into the “Carcinogenic to Humans” category, which is the highest class of cancer causing agents (the same category as cigarettes). Additionally, there’s also evidence that eating red meats may cause cancer, as they were assigned to the “Probably Carcinogenic to Humans” group.
Posted on November 6, 2015
It seems like there is a new study about vitamin D’s effects on colon cancer every few months, with each one arriving at different conclusions about whether it is helpful. The latest is a large clinical trial of vitamin D and calcium for the prevention of colorectal polyps. This trial randomly assigned 2,259 people with a history of polyps to receive one of the following:
- 1,000 units of vitamin D3
- 1,200 mg of calcium carbonate
- Placebo once a day for 3-5 years
Posted on November 3, 2015
FDA UPDATE as of November 3, 2015 – Merck has just announced that the FDA has given pembrolizumab (Keytruda) breakthrough status, which will speed up the development and review for FDA approval. The update was a result of the findings in the ongoing phase II study, which demonstrated high response rates with pembrolizumab in patients with heavily pretreated colorectal cancer with a specific type of tumor. In addition to the phase II study, Merck is planning to launch a phase III trial. We will continue to keep you updated as more details emerge.
Dr. Laura detailed the results of the phase II study that was presented at ASCO this summer back in June. Read more
Posted on October 15, 2015
For cancer patients, or anyone with a chronic disease, one of the most valuable elements of the Affordable Care Act (ACA) is that you cannot be denied health insurance based on a pre-existing condition. Unfortunately, some health plans appeared to negate this protection by offering “adverse tiering” as a plan component. What this means is particular drugs used to treat a specific condition are likely to have an extremely high co-pay or co-insurance requirement. For example, cancer and HIV drugs were most likely to be placed with high co-pays that are costly and out of reach for most Americans. What this comes down to is someone with cancer could buy health insurance without issue, but if they choose a plan with adverse tiering, they may not be able to afford the drugs used to treat their condition.